Axsome Therapeutics, Inc.
solriamfetol
major depressive disorder (MDD) with EDS symptoms
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for solriamfetol in major depressive disorder (MDD) with EDS symptoms are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In February 2026, Axsome initiated the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD with EDS symptoms.”